The underlying mechanism of chimeric antigen receptor (CAR)-T cell therapy triggering secondary T-cell cancers: Mystery of the Sphinx?
Cancer Lett
; 597: 217083, 2024 Aug 10.
Article
in En
| MEDLINE
| ID: mdl-38925363
ABSTRACT
The U.S. Food and Drug Administration (FDA) has reported cases of T-cell malignancies, including CAR-positive lymphomas, in patients receiving B cell maturation antigen (BCMA)- or CD19-targeted autologous CAR-T cell immunotherapy. These reports were derived from clinical trials and/or post-marketing adverse event data. This finding has attracted widespread attention. Therefore, it is essential to explore the potential mechanisms by which chimeric antigen receptor (CAR)-T cell therapy triggers secondary T-cell cancers to further guarantee the safety of CAR-T cell therapy.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
T-Lymphocytes
/
Immunotherapy, Adoptive
/
Antigens, CD19
/
Receptors, Chimeric Antigen
Limits:
Humans
Language:
En
Journal:
Cancer Lett
Year:
2024
Document type:
Article
Affiliation country:
China